Plcg2 — Phospholipase C Gamma 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PLCG2 encodes phospholipase C gamma 2 (PLCγ2), a signaling enzyme predominantly expressed in hematopoietic cells and microglia. Genetic and functional data place PLCγ2 in the risk architecture of Alzheimer's disease, Lewy body dementia, and related proteinopathies [1]. PLCγ2 operates in the TREM2 signaling axis, where both TREM2 loss-of-function and PLCγ2 gain-of-function variants can alter microglial responses relevant to neurodegeneration.
¶ Lipid Signaling and Calcium Mobilization
PLCγ2 catalyzes PIP2 hydrolysis in response to receptor activation:
- Upstream receptors: PLCγ2 is activated downstream of TREM2, Fc receptors, B cell receptors, integrins, and [Toll-like receptors (TLRs)]
- DAG production: Activates protein kinase C (PKC) and RAS/[MAPK] signaling cascades
- IP3 generation: Triggers calcium release from the endoplasmic reticulum, driving NFAT transcription factor activation and cytokine gene expression
- Microglial activation: PLCγ2 integrates signals from multiple innate immune receptors to coordinate microglial phagocytosis, cytokine production, and chemotaxis
PLCγ2 is a central node in microglial signaling:
- TREM2-PLCγ2 axis: TREM2 activation engages DAP12/TYROBP signaling, which phosphorylates and activates PLCγ2. This axis is essential for microglial chemotaxis toward amyloid plaques and phagocytic clearance of amyloid-beta [1]
- Disease-associated microglia (DAM): PLCγ2 signaling promotes transition from homeostatic microglia
A landmark 2025 study revealed a previously unrecognized upstream regulatory role for PLCG2 in the TREM2-mediated immune response. Rather than simply acting as a downstream effector of TREM2, PLCγ2 modulates TREM2 expression and signaling itself in response to AD pathology, creating a bidirectional regulatory circuit [3]. This finding fundamentally changes the understanding of the TREM2-PLCγ2 axis — PLCγ2 is not merely a signal transducer but an active modulator of the receptor that activates it.
The P522R variant (rs72824905) is a rare coding variant (minor allele frequency ≈ 0.8% in European populations) identified as protective against AD in a landmark exome-sequencing study [1]. Key features:
- Reduces AD risk by approximately 30% (OR = 0.68, P = 5.4 × 10⁻¹⁰)
- Protects against multiple dementias: Also protective against FTD and Lewy body dementia, suggesting a shared immune-mediated protective mechanism across proteinopathies
- Is a functional hypermorph: The P522R substitution increases PLCγ2 enzymatic activity by enhancing its basal and receptor-stimulated catalytic rate, without affecting protein expression levels [2]
- Modulates tau pathology: P522R carriers with mild cognitive impairment show reduced tau burden and slower disease progression [8]
Research has revealed multiple mechanisms by which the P522R hypermorph confers neuroprotection:
- Enhanced Amyloid-Beta clearance: P522R-expressing microglia and suggest that PLCG2-targeted therapies may need to be tailored by sex
¶ Delayed AD Onset and APOE epsilon4 Interaction
Population genetics data indicate that protective PLCG2 variants may delay symptom onset in some carriers, including individuals with APOE - UniProt: PLCγ2
The study of Plcg2 — Phospholipase C Gamma 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Chan JM, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39(11):1593-1609.e12. DOI:10.1016/j.ccell.2021.09.008
- Baysac K, et al. PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants. J Allergy Clin Immunol. 2024;153(1):280-291. DOI:10.1016/j.jaci.2023.08.036
- Magno L, et al. Alzheimer's Disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11(1):76. DOI:10.1186/s13195-019-0469-0
- Tsai AP, et al. Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer's Disease. Immunity. 2023;56(10):2274-2289.e6. DOI:10.1016/j.immuni.2023.08.008
- Chester JG, et al. PLCG2 variants in cherubism. J Allergy Clin Immunol. 2024;153(2):586-590. DOI:10.1016/j.jaci.2024.01.016
- Schmidt R, et al. Base-editing mutagenesis maps alleles to tune human T cell functions. Nature. 2024;625(7996):805-812. DOI:10.1038/s41586-023-06835-6
- Wang E, et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. N Engl J Med. 2022;387(1):45-57. DOI:10.1056/NEJMoa2114110
- Parker L, et al. Phospholipase C-Gamma 2 Activity in Familial Steroid-Sensitive Nephrotic Syndrome. Pediatr Res. 2019;85(4):521-527. DOI:10.1038/s41390-018-0259-6
- Chan JM et al., Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer (2021)
- Baysac K et al., PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants (2024)
- Magno L et al., Alzheimer's Disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph (2019)
- Tsai AP et al., Genetic variants of phospholipase C-γ2 alter the phenotype and function of microglia and confer differential risk for Alzheimer's Disease (2023)
- Chester JG et al., PLCG2 variants in cherubism (2024)
- Schmidt R et al., Base-editing mutagenesis maps alleles to tune human T cell functions (2024)
- Wang E et al., Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors (2022)
- Parker L et al., Phospholipase C-Gamma 2 Activity in Familial Steroid-Sensitive Nephrotic Syndrome (2019)